Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,524 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline (Placebo Control) Clear all
Completed Phase 3 Interventional Results available

A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)

NCT05139316
View directory record Official record
Conditions
Glycogen Storage Disease Type IA
Interventions
DTX401, Placebo, Oral prednisolone, Placebo for oral prednisolone
Genetic · Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
8 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Orange, California • Aurora, Colorado • Farmington, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Prevention of Narcotic-Induced Nausea

NCT00541671
View directory record Official record
Conditions
Nausea
Interventions
Saline, Phenergan
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial

NCT05321121
View directory record Official record
Conditions
Rib Fractures, Pain, Acute
Interventions
Dexmedetomidine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 4 Interventional

Intravenous Ibuprofen for Laparoscopic Bariatric Surgery

NCT01707251
View directory record Official record
Conditions
Obesity
Interventions
Intravenous Ibuprofen, Saline
Drug
Lead sponsor
Jacobi Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

NCT01391312
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin Type A, normal saline (placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
East Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

NCT01992536
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenABCWY+OMV, MenABCWY+¼OMV, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 25 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 1Phase 2 Interventional

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

NCT05683834
View directory record Official record
Conditions
Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions
Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Not applicable Interventional

IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction

NCT01226563
View directory record Official record
Conditions
Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction
Interventions
IK-5001, Saline Solution
Device
Lead sponsor
Bellerophon BCM LLC
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients

NCT00470600
View directory record Official record
Conditions
Pain
Interventions
Caldolor, Normal Saline
Drug · Other
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Mobile, Alabama • Little Rock, Arkansas • Arcadia, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 15, 2026, 4:48 PM EDT
Not listed Not applicable Interventional

TIMBER Psychotherapy and Ketamine Single Infusion in Chronic PTSD

NCT02766192
View directory record Official record
Conditions
PTSD
Interventions
Ketamine, TIMBER Psychotherapy, Placebo (normal saline)
Drug · Behavioral
Lead sponsor
The Cooper Health System
Other
Eligibility
21 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack

NCT01230411
View directory record Official record
Conditions
Episodic Migraine
Interventions
saline placebo, Ibuprofen
Other · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 15, 2026, 4:48 PM EDT
Terminated Phase 2 Interventional Results available

A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder

NCT02234011
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

NCT02885636
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Left-Sided, Left-Sided Heart Failure
Interventions
Albuterol, Saline placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 15, 2026, 4:48 PM EDT
Terminated Phase 1 Interventional

Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections

NCT03038971
View directory record Official record
Conditions
Allergic Conjunctivitis, Allergic Rhinitis
Interventions
Dose Level 1, Dose Level 2, Placebo
Biological
Lead sponsor
Woodmont Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 15, 2026, 4:48 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

NCT03862430
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
NanO2TM, Placebo Saline Infusion
Drug
Lead sponsor
NuvOx LLC
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Tucson, Arizona • Orange, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin MEG Study

NCT02568709
View directory record Official record
Conditions
Schizophrenia, Oxytocin, Magnetoencephalography (MEG), Social Cognition
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 15, 2026, 4:48 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose and Multiple Ascending Dose Study of AVR-48

NCT06847698
View directory record Official record
Conditions
Safety Issues, Tolerability, Pharmacokinetics, Pharmacodynamics
Interventions
AVR-48, Placebo
Drug
Lead sponsor
AyuVis Research, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 15, 2026, 4:48 PM EDT
Recruiting Phase 2 Interventional

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

NCT04049331
View directory record Official record
Conditions
Hypogonadism, Male, Fatigue Syndrome, Chronic
Interventions
Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], placebo
Drug · Other
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 54 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3462817 in Participants With Rheumatoid Arthritis

NCT04634253
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, LY3462817
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Mesa, Arizona • Phoenix, Arizona • Palm Desert, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02788045
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 15, 2026, 4:48 PM EDT
Withdrawn Phase 2 Interventional

Mechanisms Underlying Predictors of Success From Obesity Surgery

NCT02697253
View directory record Official record
Conditions
Obesity
Interventions
Exendin 9-39 and Sitagliptin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 15, 2026, 4:48 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

NCT07086677
View directory record Official record
Conditions
Streptococcus Pneumoniae
Interventions
PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 84 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
20
States / cities
Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers

NCT07644195
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TRL1068, a human monoclonal antibody
Drug
Lead sponsor
Trellis Bioscience LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Recruiting Phase 3 Interventional

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 4:48 PM EDT